Frequency of acute GVHD of the gut and liver among 2500 patients undergoing first allogeneic transplants
| . | Frequency . | Percent . |
|---|---|---|
| Overall: gut ± liver GVHD | 1580/2500 | 63 |
| Gut + liver GVHD | 200/2500 | 8 |
| Gut GVHD, no liver GVHD | 1354/2500 | 54 |
| Liver GVHD, no gut GVHD | 26/2500 | 1 |
| Skin GVHD present | 22/2500 | 0.88 |
| Skin GVHD absent* | 4/2500 | 0.16 |
| No gut or liver GVHD | 920/2500 | 37 |
| . | Frequency . | Percent . |
|---|---|---|
| Overall: gut ± liver GVHD | 1580/2500 | 63 |
| Gut + liver GVHD | 200/2500 | 8 |
| Gut GVHD, no liver GVHD | 1354/2500 | 54 |
| Liver GVHD, no gut GVHD | 26/2500 | 1 |
| Skin GVHD present | 22/2500 | 0.88 |
| Skin GVHD absent* | 4/2500 | 0.16 |
| No gut or liver GVHD | 920/2500 | 37 |
Patients undergoing first allogeneic transplants at the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance from July 1, 2003, through December 31, 2014 (G.B.M., unpublished observations).
These 4 patients had acute GVHD of the liver but no gut or skin GVHD. Their severity of liver disease was stage 1 (peak total serum bilirubin 2-3 mg/dL) in 2 patients, stage 2 (>3-6 mg/dL) in 1 patient, and stage 4 (>15 mg/dL) in 1 patient.